cvot tirzepatide π‘ New insight in diabetes care: In patients with T2DM and ASCVD, the SURPASS-CVOT trial found that was noninferior to dulaglutide for major cardiovascular events (12.2% vs 13.1%; HR 0.92). What Tirzepatide Matches Dulaglutide in Large
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours Β· Estimated delivery Aug 9 - Aug 14












.webp)



-1775582746855.png&w=3840&q=75)








